DataSheet6_Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer.PDF

Background: This study aimed to confirm the role of enhancer RNAs (eRNAs) in gastric cancer and their clinical utility.Methods: We used Cox survival and relevance analysis to identify the candidate eRNAs in gastric cancer and performed Gene Ontology and Reactome pathway enrichment to determine the potential functions of eRNAs. Correlation between eRNA, tumor-infiltrating immune cells, and drug sensitivity was then analyzed.Results:CDK6-AS1, a long non-coding RNA cyclin-dependent kinase 6, may serve as a poor potential prognostic biomarker candidate in gastric cancer with a positive correlation with its target gene CDK6. The low CDK6-AS1 expression group showed more frequent mutated driver genes than the high expression group. Moreover, CDK6-AS1 is involved in a key oncogenic pathway of the cell cycle and RNA transcription. CDK6-AS1 also shows dysregulations and associations with prognosis at the pan-cancer level. This eRNA may also be associated with immune cell infiltration and drug sensitivity.Conclusion:CDK6-AS1 may be a potential prognostic biomarker and chemotherapeutic drug sensitivity predictor in gastric cancer.

本研究旨在确认增强型RNA（eRNA）在胃癌中的作用及其临床应用价值。研究方法：本研究采用Cox生存分析和相关性分析以鉴定胃癌中的候选eRNA，并通过基因本体和Reactome通路富集分析来确定eRNA的潜在功能。随后，分析了eRNA与肿瘤浸润免疫细胞及药物敏感性之间的相关性。研究结果：CDK6-AS1，一种长非编码RNA，可能作为胃癌中一种不良预后的潜在生物标志物候选者，与其靶基因CDK6存在正相关。低CDK6-AS1表达组中比高表达组更频繁地出现突变驱动基因。此外，CDK6-AS1参与细胞周期和RNA转录的关键致癌途径，并在全癌水平上显示出失调与预后相关。该eRNA还可能与免疫细胞浸润和药物敏感性相关。结论：CDK6-AS1可能成为胃癌中一种潜在的预后生物标志物和化疗药物敏感性预测因子。